ReviewTranslational research : the journal of laboratory and clinical medicine2017
The gut microbiota and inflammatory bowel diseases.
Review in Translational research : the journal of laboratory and clinical medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 146 citations in OpenAlex.
- Adjunctive treatment with probiotics partially alleviates symptoms and reduces inflammation in patients with irritable bowel syndrome.European journal of nutrition · 2021Trial
- The Effects of Reduced Glutathione on Growth Performance, Intestinal Inflammation, and Gut Microbiota in Immune-Stressed Broiler Chickens.Animals : an open access journal from MDPI · 2026Article
- Microbiota-gut-brain axis multi-organ chip construction and applications in drug evaluation.iMetaOmics · 2025Review
- Homeostasis of Gut Microbiota Protects against Susceptibility to Fungal Pneumonia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Mechanism and Clinical Application Prospects of Mitochondrial DNA Single Nucleotide Polymorphism in Neurodegenerative Diseases.Neurochemical research · 2024Review
- Targeting the Intestinal Microbiota: A Novel Direction in the Treatment of Inflammatory Bowel Disease.Biomedicines · 2024Review
- Effect of Mutant and Engineered High-Acetate-ProducingNutrients · 2024Article
- Understanding bovine embryo elongation: a transcriptomic study of trophoblastic vesicles.Frontiers in physiology · 2024Article
- Article
- NLRP3 Inflammasome and Gut Dysbiosis Linking Diabetes Mellitus and Inflammatory Bowel Disease.Archives of internal medicine research · 2024Article
- Diagnosis of Crohn's disease and ulcerative colitis using the microbiome.BMC microbiology · 2023Article
- Insulin alleviates murine colitis through microbiome alterations and bile acid metabolism.Journal of translational medicine · 2023Article
- Fluorimetric Reusable Polymeric Sensor for Hydrogen Sulfide Detection.Journal of fluorescence · 2023Article
- Association between inflammatory bowel disease and Parkinson's disease: a prospective cohort study of 468,556 UK biobank participants.Frontiers in aging neuroscience · 2023Article
- High Acetate Concentration Protects Intestinal Barrier and Exerts Anti-Inflammatory Effects in Organoid-Derived Epithelial Monolayer Cultures from Patients with Ulcerative Colitis.International journal of molecular sciences · 2023Article
- Microbial Interdomain Interactions Delineate the Disruptive Intestinal Homeostasis in Clostridioides difficile Infection.Microbiology spectrum · 2022Article
- Role of short chain fatty acids in gut health and possible therapeutic approaches in inflammatory bowel diseases.World journal of clinical cases · 2022Review
- Insight into the Relationship between Oral Microbiota and the Inflammatory Bowel Disease.Microorganisms · 2022Review
- Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches.Biomedicines · 2022Review
- Ulcerative Colitis Seems to Imply Oral Microbiome Dysbiosis.Current issues in molecular biology · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Inflammatory bowel diseases (IBDs) are chronic diseases of unclear etiology that affect over 1 million individuals in the United States and over 2.5 million people in Europe. However, they are also expanding globally, affecting populations in Asia, South America, and the Middle East as they become more industrialized. These diseases are believed to arise from the convergence of genetic, environmental, and microbial factors that trigger aberrant immune and tissue responses, resulting in intestinal inflammation. Advances in cultivation-independent investigations, experimental models, and bioinformatics approaches have improved our understanding of the role of gut microbiota in IBD. However, determining and understanding the functional consequences of gut dysbiosis and altered host-microbiota interactions in IBD remain a challenge due to the limits of current experimental models and difficulty in establishing causal links in human-based investigations. Continued development of new methodologies and improvements in clinical study design are needed to better understand the interplay of genetic, microbial, and immunological factors in IBD. This knowledge can then be applied clinically to improve therapeutic strategies and outcomes for IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.